-
公开(公告)号：US20210205535A1
公开(公告)日：2021-07-08
申请号：US17142425
申请日：2021-01-06
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on the history of glucose values and insulin deliveries for the user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal or exercise by the user.
-
公开(公告)号：US20200069875A1
公开(公告)日：2020-03-05
申请号：US16116071
申请日：2018-08-29
Applicant: Insulet Corporation
Inventor： David NAZZARO , John D`ARCO , Jason O'CONNOR , Ian MCLAUGHLIN
Abstract: A drug delivery system having a drug delivery device and an associated sensor is provided. The sensor can be associated with a sensing site on user. The drug delivery device can be positioned over the sensor in any rotational position and can be associated with an infusion site on the user. The close positioning of the sensor and the drug delivery device allows data from the sensor to be relayed to the drug delivery device and then on to a remote control device. Further, the drug delivery device can be replaced at the end of its duration of use, which is shorter than the duration of use of the sensor, without disturbing the sensor. Subsequent drug delivery devices can then be used with the sensor while allowing each corresponding infusion site to be changed, thereby providing more efficient operation of the drug delivery system.
-
33.发明申请公开(公告)号：US20250144295A1
公开(公告)日：2025-05-08
申请号：US19017941
申请日：2025-01-13
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR
Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.
-
公开(公告)号：US20250065039A1
公开(公告)日：2025-02-27
申请号：US18885257
申请日：2024-09-13
Applicant: INSULET CORPORATION
Inventor： Jason O'CONNOR , Matthew ALLES , Robert SANZONE , Craig BRODEUR , Joseph MELO , Christopher WILLIAMS , Noel SCHAEFFER
IPC: A61M5/142
Abstract: The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.
-
公开(公告)号：US20250025631A1
公开(公告)日：2025-01-23
申请号：US18909572
申请日：2024-10-08
Applicant: INSULET CORPORATION
Inventor： James GRAHAM , Joon Bok LEE , Jason O'CONNOR
IPC: A61M5/172 , A61B5/00 , A61B5/145 , A61B5/1495 , A61M5/142 , A61M5/168 , G16H10/60 , G16H20/00 , G16H20/10 , G16H20/17 , G16H40/67
Abstract: Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.
-
Patent Agency Ranking
36.发明公开公开(公告)号：US20240009393A1
公开(公告)日：2024-01-11
申请号：US18474566
申请日：2023-09-26
Applicant: INSULET CORPORATION
Inventor： Steven CARDINALI , Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG
CPC classification number: A61M5/1723 , G16H20/17 , G16H10/60 , A61B5/14532 , G16H15/00
Abstract: Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.
-
公开(公告)号：US20230381414A1
公开(公告)日：2023-11-30
申请号：US18323538
申请日：2023-05-25
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
CPC classification number: A61M5/1723 , G16H20/17 , G16H10/60
Abstract: Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.
-
公开(公告)号：US20220395638A1
公开(公告)日：2022-12-15
申请号：US17839647
申请日：2022-06-14
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR
IPC: A61M5/172
Abstract: The disclosed embodiments are directed to methods for adjusting, on a per individual basis, the maximum delivery limit of insulin delivered to a diabetic person via an automatic insulin delivery system, particularly for a diabetic who receives basal or bolus doses of insulin via an automatic insulin delivery system. Various embodiments of the method disclosed herein may be incorporated into a dosing algorithm of an automatic insulin delivery system.
-
公开(公告)号：US20220331519A1
公开(公告)日：2022-10-20
申请号：US17718663
申请日：2022-04-12
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE
IPC: A61M5/172 , A61B5/145 , A61B5/1495 , A61M5/142 , G16H40/40
Abstract: Exemplary embodiments may compensate for loss of calibration by sensors that provide sensed analyte measurements to delivery devices. The exemplary embodiments may obtain one or more calibrated analyte measurements, such as by using techniques to obtain that the analyte measurement value that are known to produce properly calibrated analyte values. The one or more calibrated analyte measurements are compared to a recent analyte measurement to determine a negative or positive offset. The offset may be added to the recent analyte measurement to generate an updated analyte measurement that reflects the calibrated analyte measurement. In addition, past analyte measurement values within a time window may be updated as well by adding the offset to the past analyte measurement values. The exemplary embodiments may also compensate for the past over-delivery or under-delivery of an agent by the delivery device due to the loss of calibration.
-
公开(公告)号：US20220288311A1
公开(公告)日：2022-09-15
申请号：US17687808
申请日：2022-03-07
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.013 seconds)
